For research and educational purposes only. Not medical advice.
Anamorelin Reference
Educational, not medical advice reference for Anamorelin: GH Release, Fat Loss; regulatory status, evidence posture, source review, and schedule…
Reference summary
Phase 3 trial data in cancer cachexia have been published. pepSmart displays anamorelin as trial-context plus non-US-approval educational content; US framing is investigational only.
Regulatory and posture
- Categories
- GH Release, Fat Loss
- Aliases
- Adlumiz (Japan), ONO-7643, Oral ghrelin agonist
- Evidence posture
- human - Approved in Japan (Adlumiz) for cancer cachexia, not FDA-approved in the US. Community body-composition framing extrapolates beyond the approved oncology indication.
- Regulatory status
- Investigational in the United States. Anamorelin is approved in Japan for cancer cachexia under the brand Adlumiz. There is no FDA-approved US drug label, and US use is not approved for any indication.
- Content review status
- investigational verified
Selected public sources
Related tools
- Protocol builder overview - Public overview of the Pro protocol builder.